China SXT Pharmaceuticals annual depreciation and amortization
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
China SXT Pharmaceuticals Depreciation & Amortization Growth & History (SXTC)
China SXT Pharmaceuticals's depreciation and amortization was $73,668 for fiscal 2026.
View full China SXT Pharmaceuticals company overviewChina SXT Pharmaceuticals annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2026 | 2026-03-31 | $73,668 | −$8,629 | −10.49% |
| 2025 | 2025-03-31 | $82,297 | −$120,950 | −59.51% |
| 2024 | 2024-03-31 | $203,247 | −$46,915 | −18.75% |
| 2023 | 2023-03-31 | $250,162 | −$69,845 | −21.83% |
| 2022 | 2022-03-31 | $320,007 | −$25,407 | −7.36% |
| 2021 | 2021-03-31 | $345,414 | $13,577 | +4.09% |
| 2020 | 2020-03-31 | $331,837 | $150,920 | +83.42% |
| 2019 | 2019-03-31 | $180,917 | $51,478 | +39.77% |
| 2018 | 2018-03-31 | $129,439 | $30,211 | +30.45% |
| 2017 | 2017-03-31 | $99,228 | — | — |
China SXT Pharmaceuticals depreciation and amortization trends
Over the last five fiscal years, China SXT Pharmaceuticals's depreciation and amortization decreased from $345,414 to $73,668, a change of −$271,746.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review China SXT Pharmaceuticals source filings ↗